{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+P.G12D",
    "query": {
      "condition": "KRAS P.G12D"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+P.G12D&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T09:18:18.371Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06364696",
      "title": "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASP4396",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-04-16",
      "completion_date": "2026-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 7,
      "location_summary": "Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06364696"
    },
    {
      "nct_id": "NCT04853017",
      "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Minimal Residual Disease",
        "KRAS G12D",
        "KRAS G12R",
        "NRAS G12D",
        "NRAS G12R",
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer",
        "Cholangiocarcinoma",
        "Bile Duct Cancer",
        "Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "ELI-002 2P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elicio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-10-04",
      "completion_date": "2024-09-24",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04853017"
    },
    {
      "nct_id": "NCT07621718",
      "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Cancer Metastatic",
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Pancreatic Adenocarcinoma Metastatic",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Adenosquamous Carcinoma"
      ],
      "interventions": [
        {
          "name": "Zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin (Calcium Folinate)",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (GEM)",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 670,
      "start_date": "2026-05-22",
      "completion_date": "2030-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07621718"
    },
    {
      "nct_id": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "CRC (Colorectal Cancer)",
        "Metastatic Non-Small Lung Cell Cancer",
        "Metastatic Colorectal Cancer (CRC)",
        "KRAS G12A",
        "KRAS G12C",
        "KRAS G12D",
        "KRAS G12S",
        "KRAS G12V",
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Advanced Lung Carcinoma",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "BBO-11818",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Platinum chemotherapy (cisplatin or carboplatin)",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 665,
      "start_date": "2025-03-31",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06917079"
    },
    {
      "nct_id": "NCT01833143",
      "title": "Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2013-04-11",
      "completion_date": "2019-08-28",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833143"
    },
    {
      "nct_id": "NCT06040541",
      "title": "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Colorectal Cancer (CRC)",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-9805",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2023-09-07",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 17,
      "location_summary": "Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06040541"
    },
    {
      "nct_id": "NCT07629960",
      "title": "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Colorectal Neoplasms",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "BLU-924",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2026-06-30",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07629960"
    },
    {
      "nct_id": "NCT06973564",
      "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "JAB-23E73",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jacobio Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 294,
      "start_date": "2025-05-29",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 4,
      "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973564"
    },
    {
      "nct_id": "NCT06227377",
      "title": "QTX3034 in Patients With KRAS G12D Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "QTX3034",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Quanta Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-02-05",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06227377"
    },
    {
      "nct_id": "NCT07456046",
      "title": "A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "KRAS P.G12D"
      ],
      "interventions": [
        {
          "name": "D3S-003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "D3 Bio (Wuxi) Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2026-05-29",
      "completion_date": "2028-01-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-07-23T09:18:18.371Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07456046"
    }
  ]
}